An Overview of ADAM9: Structure, Activation, and Regulation in Human Diseases

被引:62
|
作者
Chou, Cheng-Wei [1 ,2 ]
Huang, Yu-Kai [1 ]
Kuo, Ting-Ting [3 ]
Liu, Jing-Pei [1 ]
Sher, Yuh-Pyng [1 ,3 ,4 ]
机构
[1] China Med Univ, Grad Inst Biomed Sci, Taichung 404, Taiwan
[2] Taichung Vet Gen Hosp, Div Hematol Med Oncol, Dept Med, Taichung 407, Taiwan
[3] China Med Univ Hosp, Ctr Mol Med, Taichung 404, Taiwan
[4] China Med Univ, Chinese Med Res Ctr, Taichung 404, Taiwan
关键词
ADAM9; biological function; inflammation; cancer; HEPATOCELLULAR-CARCINOMA; PANCREATIC-CANCER; LUNG-CANCER; CELL-PROLIFERATION; TARGETING ADAM9; METALLOPROTEASE-DISINTEGRIN; CRYSTAL-STRUCTURES; ENDOTHELIAL-CELL; TUMOR-CELLS; EXPRESSION;
D O I
10.3390/ijms21207790
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
ADAM9 (A disintegrin and a metalloprotease 9) is a membrane-anchored protein that participates in a variety of physiological functions, primarily through the disintegrin domain for adhesion and the metalloprotease domain for ectodomain shedding of a wide variety of cell surface proteins. ADAM9 influences the developmental process, inflammation, and degenerative diseases. Recently, increasing evidence has shown that ADAM9 plays an important role in tumor biology. Overexpression of ADAM9 has been found in several cancer types and is correlated with tumor aggressiveness and poor prognosis. In addition, through either proteolytic or non-proteolytic pathways, ADAM9 promotes tumor progression, therapeutic resistance, and metastasis of cancers. Therefore, comprehensively understanding the mechanism of ADAM9 is crucial for the development of therapeutic anti-cancer strategies. In this review, we summarize the current understanding of ADAM9 in biological function, pathophysiological diseases, and various cancers. Recent advances in therapeutic strategies using ADAM9-related pathways are presented as well.
引用
收藏
页码:1 / 22
页数:22
相关论文
共 50 条
  • [21] ADAM9 Promotes Lung Cancer Metastases to Brain by a Plasminogen Activator-Based Pathway
    Lin, Chen-Yuan
    Chen, Hung-Jen
    Huang, Cheng-Chung
    Lai, Liang-Chuan
    Lu, Tzu-Pin
    Tseng, Guan-Chin
    Kuo, Ting-Ting
    Kuok, Qian-Yu
    Hsu, Jennifer L.
    Sung, Shian-Ying
    Hung, Mien-Chie
    Sher, Yuh-Pyng
    CANCER RESEARCH, 2014, 74 (18) : 5229 - 5243
  • [22] The Effect of Disintegrin-Metalloproteinase ADAM9 in Gastric Cancer Progression
    Kim, Jeong Min
    Jeung, Hei-Cheul
    Rha, Sun Young
    Yu, Eun Jeong
    Kim, Tae Soo
    Shin, You Keun
    Zhang, Xianglan
    Park, Kyu Hyun
    Park, Seung Woo
    Chung, Hyun Cheol
    Powis, Garth
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (12) : 3074 - 3085
  • [23] Sorting nexin 9 (SNX9) regulates levels of the transmembrane ADAM9 at the cell surface
    Mygind, Kasper J.
    Stoeriko, Theresa
    Freiberg, Marie L.
    Samsoe-Petersen, Jacob
    Schwarz, Jeanette
    Andersen, Olav M.
    Kveiborg, Marie
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2018, 293 (21) : 8077 - 8088
  • [24] Retinoids Decrease Soluble MICA Concentration by Inhibiting the Enzymatic Activity of ADAM9 and ADAM10
    Otoyama, Yumi
    Arai, Jun
    Goto, Kaku
    Nozawa, Hisako
    Nakagawa, Ryo
    Muroyama, Ryosuke
    Sugiura, Ikuya
    Nakajima, Yoko
    Kajiwara, Atsushi
    Tojo, Masayuki
    Ichikawa, Yuki
    Uozumi, Shojiro
    Shimozuma, Yuu
    Uchikoshi, Manabu
    Sakaki, Masashi
    Kato, Naoya
    Yoshida, Hitoshi
    ANTICANCER RESEARCH, 2021, 41 (05) : 2307 - 2320
  • [25] Licochalcone A inhibits the invasive potential of human glioma cells by targeting the MEK/ERK and ADAM9 signaling pathways
    Huang, Chien-Feng
    Yang, Shun-Fa
    Chiou, Hui-Ling
    Hsu, Wen-Hung
    Hsu, Jen-Chieh
    Liu, Chung-Jung
    Hsieh, Yi-Hsien
    FOOD & FUNCTION, 2018, 9 (12) : 6197 - 6205
  • [26] ADAM9 drives the immunosuppressive microenvironment by cholesterol biosynthesis-mediated activation of IL6-STAT3 signaling for lung tumor progression
    Liu, Jing-Pei
    Shen, Kuan-Yin
    Cheng, Wei-Chung
    Chang, Wei-Chao
    Hsieh, Chih-Ying
    Lo, Chia-Chien
    Kuo, Ting-Ting
    Lin, Ching-Chan
    Liu, Shih-Jen
    Huang, Wen-Chin
    Sher, Yuh-Pyng
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (04):
  • [27] Characterization of the catalytic properties of the membrane-anchored metalloproteinase ADAM9 in cell-based assays
    Maretzky, Thorsten
    Swendeman, Steven
    Mogollon, Elin
    Weskamp, Gisela
    Sahin, Umut
    Reiss, Karina
    Blobel, Carl P.
    BIOCHEMICAL JOURNAL, 2017, 474 (09) : 1467 - 1479
  • [28] LPS activates ADAM9 dependent shedding of ACE from endothelial cells
    English, William R.
    Corvol, Pierre
    Murphy, Gillian
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2012, 421 (01) : 70 - 75
  • [29] An ADAM9 mutation in canine cone-rod dystrophy 3 establishes homology with human cone-rod dystrophy 9
    Goldstein, Orly
    Mezey, Jason G.
    Boyko, Adam R.
    Gao, Chuan
    Wang, Wei
    Bustamante, Carlos D.
    Anguish, Lynne J.
    Jordan, Julie Ann
    Pearce-Kelling, Susan E.
    Aguirre, Gustavo D.
    Acland, Gregory M.
    MOLECULAR VISION, 2010, 16 (167-70): : 1549 - 1569
  • [30] Loss of ADAM9 Leads to Modifications of the Extracellular Matrix Modulating Tumor Growth
    Abety, Anna N.
    Pach, Elke
    Giebeler, Nives
    Fromme, Julia E.
    Aramadhaka, Lavakumar Reddy
    Mauch, Cornelia
    Fox, Jay W.
    Zigrino, Paola
    BIOMOLECULES, 2020, 10 (09) : 1 - 12